|
|
Blood, 15 March 2004, Vol. 103, No. 6, pp. 2407-2409.
Prepublished online as a Blood First Edition Paper on November 20, 2003; DOI 10.1182/blood-2003-10-3390.
Previous Article | Table of Contents | Next Article 
RED CELLS Brief report
Screening hepcidin for mutations in juvenile hemochromatosis: identification of a new mutation (C70R)
Antonella Roetto,
Filomena Daraio,
Paolo Porporato,
Roberta Caruso,
Timothy M. Cox,
Mario Cazzola,
Paolo Gasparini,
Alberto Piperno, and
Clara Camaschella
From the Dipartimento di Scienze Cliniche e Biologiche, Università di Torino, Torino, Italy; Divisione di Ematologia, Instituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Ospedale Pediatrico Bambin Gesù, Roma, Italy; Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Dipartimento di Medicina Interna e Oncologia, IRCCS Policlinico San Matteo, Pavia, Italy; Genetica Medica, Dipartimento di Patologia Generale, II Università di Napoli and Tigem (Telethon Institute of Genetics and Medicine), Napoli, Italy; and Clinica Medica, Azienda Ospedaliera San Gerardo, Monza, Italy.
Juvenile or type 2 hemochromatosis (JH) is a genetic disease caused by increased intestinal iron absorption that leads to early massive iron overload. The main form of the disease is caused by mutations in a still unknown gene on chromosome 1q. Recently, we recognized a second type of JH with clinical features identical to the 1q-linked form, caused by mutations in the gene encoding hepcidin (HEPC). Hepcidin is a hepatic antimicrobial-like peptide whose role in iron homeostasis was first defined in animal models; deficiency of hepcidin in mice leads to iron overload, whereas its hepatic overexpression in transgenic animals causes iron deficiency. To define the prevalence of HEPC mutations in JH we screened the HEPC gene for mutation in 21 unrelated JH subjects. We identified a new mutation (C70R), which affects 1 of the 8 conserved cysteines that form the disulfide bonds and are critical for the stability of the polypeptide.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. A. Browne and D. Reddan
Potential role of bone morphogenetic protein (BMP) signalling as a potential therapeutic target for modification of iron balance
Nephrol. Dial. Transplant.,
January 1, 2009;
24(1):
28 - 30.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Nagayoshi, M. Nakayama, S. Suzuki, J. Hokamaki, H. Shimomura, K. Tsujita, M. Fukuda, T. Yamashita, Y. Nakamura, S. Sugiyama, et al.
A Q312X mutation in the hemojuvelin gene is associated with cardiomyopathy due to juvenile haemochromatosis
Eur J Heart Fail,
October 1, 2008;
10(10):
1001 - 1006.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Fabio, F. Minonzio, P. Delbini, A. Bianchi, and M. D. Cappellini
Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH)
Blood,
January 1, 2007;
109(1):
362 - 364.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Camaschella
Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders
Blood,
December 1, 2005;
106(12):
3710 - 3717.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Porto, A. Roetto, F. Daraio, J. P. Pinto, S. Almeida, C. Bacelar, E. Nemeth, T. Ganz, and C. Camaschella
A Portuguese patient homozygous for the -25G>A mutation of the HAMP promoter shows evidence of steady-state transcription but fails to up-regulate hepcidin levels by iron
Blood,
October 15, 2005;
106(8):
2922 - 2923.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Janosi, H. Andrikovics, K. Vas, A. Bors, M. Hubay, Z. Sapi, and A. Tordai
Homozygosity for a novel nonsense mutation (G66X) of the HJV gene causes severe juvenile hemochromatosis with fatal cardiomyopathy
Blood,
January 1, 2005;
105(1):
432 - 432.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K J H Robson, A T Merryweather-Clarke, E Cadet, V Viprakasit, M G Zaahl, J J Pointon, D J Weatherall, and J Rochette
Recent advances in understanding haemochromatosis: a transition state
J. Med. Genet.,
October 1, 2004;
41(10):
721 - 730.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. W. Huang, I. Rubio-Aliaga, J. P. Kushner, N. C. Andrews, and M. D. Fleming
Identification of a novel mutation (C321X) in HJV
Blood,
October 1, 2004;
104(7):
2176 - 2177.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Matthes, P. Aguilar-Martinez, L. Pizzi-Bosman, R. Darbellay, L. Rubbia-Brandt, E. Giostra, M. Michel, T. Ganz, and P. Beris
Severe hemochromatosis in a Portuguese family associated with a new mutation in the 5'-UTR of the HAMP gene
Blood,
October 1, 2004;
104(7):
2181 - 2183.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Lanzara, A. Roetto, F. Daraio, S. Rivard, R. Ficarella, H. Simard, T. M. Cox, M. Cazzola, A. Piperno, A.-P. Gimenez-Roqueplo, et al.
Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis
Blood,
June 1, 2004;
103(11):
4317 - 4321.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|